Woodcliff Lake, NJ, April 17, 2007 – Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., today announces the completion of Eisai’s acquisition of Morphotek®, Inc. for US$325 million after excess net cash. The companies received …
Trending at Lumira Ventures
Argos Therapeutics Raises $5.0 Million in Debt Financing
Learn More-External Link
KAI Pharmaceuticals Presents Encouraging Phase 1/2 Results of a Novel Treatment for Heart Attack
Learn More-External Link
SIEMENS AND U-SYSTEMS ANNOUNCE WORLDWIDE DISTRIBUTIONAGREEMENT
MOUNTAIN VIEW and SAN JOSE, Calif., March 23, 2007 – Siemens Medical Solutions Ultrasound Division www.usa.siemens.com/medical and USystems Inc. www.u-sys.com have entered into an agreement whereby Siemens will distribute U-Systems’ SomoVu™ automated breast ultrasound system on a worldwide scale. The …
Argos Therapeutics Awarded U.S. Patent for CD83 Protein for Use in Immunological Disorders
Learn More-External Link
Archemix is Granted Two European Patents for the Identification and Use of Therapeutic Aptamers
Cambridge, MA – March 8, 2007 – Archemix Corp., the leading aptamer therapeutics company, announced today the issuance of two key, broad patents by the European Patent Office (“EPO”). The patents, EP 0 786 469 and EP 0 668 931, broadly …
Replidyne Phase II Pediatric Trial Meets Primary Objective
Learn More-External Link
ActivBiotics, Inc. Announces Initiation of Phase II Study In Carotid Atherosclerosis
Learn More-External Link
KAI to Present KAI-9803 Phase I/II Trial Data in a Late-Breaking Session of the ACC
Learn More-External Link
MAKO Surgical Corp. Closes $30 Million in Series C Funding
(FORT LAUDERDALE, FL) — MAKO Surgical Corp., an emerging orthopedic medical device company developing advanced solutions for least invasive knee surgery, announced today that it has closed on a $30 million Series C private equity financing led by funds affiliated …
Alveolus, Inc. Launches AERO™ Hybrid Tracheobronchial Stent System in U.S.
Learn More-External Link
Ception Therapeutics Raises $63 Million in Series C Financing.
MALVERN, PA – January 29, 2007 – Ception Therapeutics, Inc., an emerging biopharmaceutical company discovering and developing novel biologic and small-molecule agents to address unmet medical needs, today announced that it has raised $63 million through a Series C private …
Archemix Announces Collaboration with Pfizer to Discover Aptamer Therapeutics
CAMBRIDGE, Mass., Jan. 9 — Archemix Corp. today announced that it has signed an agreement with Pfizer focused on the discovery of first-in-class aptamers for the development and commercialization as therapeutics.As part of the collaboration, Archemix will use its proprietary …